首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >LUCIFERASE REPORTER MYCOBACTERIOPHAGES FOR EVALUATING NORBORNENE-BASED ANTITUBERCULOSIS DRUG SUSCEPTIBILITY TESTING ON MYCOBACTERIUM TUBERCULOSIS
【24h】

LUCIFERASE REPORTER MYCOBACTERIOPHAGES FOR EVALUATING NORBORNENE-BASED ANTITUBERCULOSIS DRUG SUSCEPTIBILITY TESTING ON MYCOBACTERIUM TUBERCULOSIS

机译:用于评估基于结核分枝杆菌的降冰片烯抗结核药药敏性测试的LUCFERASE REPORTER霉菌噬菌体

获取原文

摘要

Objective: In 2015, 9.6 million people around the world became sick with tuberculosis (TB) disease and 1.5 million TB-related deaths worldwide. Recent increasing incidence of multidrug-resistant (MDR; resistance to at least rifampicin (RIF) and isoniazid [INH]) and extensively drug-resistant (MDR resistance plus resistance to a fluoroquinolone and an aminoglycoside) makes TB a serious concern. Lot of research is needed to deal with this infectious disease for a better alternative in treatment or modification of these older TB drugs. The present study aimed at evaluating antimycobacterial activity of norbornene (NOR) derived INH copolymer with poly ethylene glycol (NOR- polyethylene glycol [PEG]-INH) a novel nanocarrier along with the anti-TB drug using luciferase reporter phages (LRPs). Methods: NOR derived INH accounts for 74% of INH, 24% of NOR, and 2% of PEG. H37Rv control strain, a sensitive, and a resistant strain of Mycobacterium TB (MTB) used in this study. The in vitro activity of the drug was evaluated using absolute concentration method. The resistant strain was evaluated using LRP assay to observe the minimum inhibitory concentration of the drug. Results: Reduction in light units was observed for the resistant strain exposed to plain INH and NOR-PEG-INH separately. 24% of reduction was observed in strains exposed to plain INH whereas 37% of reduction was observed in strains exposed to NOR-PEG-INH. Conclusion: NOR-based INH had better antimycobacterial activity compared to plain INH and RIF. Antimycobacterial activity of INH and RIF increases even with very low dosage with NOR conjugate.
机译:目标:2015年,全球有960万人患有结核病,全球有150万人死于结核病。最近出现的多药耐药性(MDR;至少对利福平(RIF)和异烟肼[INH]耐药)和广泛耐药性(MDR耐药性加上对氟喹诺酮和氨基糖苷的耐药性)使结核病成为一个严重的问题。对于这种传染病,需要进行大量研究,以找到更好的替代方法来治疗或改良这些较旧的结核病药物。本研究旨在通过荧光素酶报道噬菌体(LRPs)评估降冰片烯(NOR)衍生的INH共聚物与聚乙二醇(NOR-聚乙二醇[PEG] -INH)和抗结核药物一起的新型纳米载体的抗分枝杆菌活性。方法:NOR衍生的INH占INH的74%,NOR的24%和PEG的2%。 H37Rv控制菌株,该研究中使用的结核分枝杆菌(MTB)敏感菌株和耐药菌株。使用绝对浓度法评估药物的体外活性。使用LRP测定法评估抗性菌株以观察药物的最小抑制浓度。结果:观察到分别暴露于普通INH和NOR-PEG-INH的抗性菌株的光单位减少。在暴露于普通INH的菌株中观察到24%的减少,而在暴露于NOR-PEG-INH的菌株中观察到37%的减少。结论:基于NOR的INH比普通的INH和RIF具有更好的抗分枝杆菌活性。即使使用NOR偶联物剂量非常低,INH和RIF的抗分枝杆菌活性也会增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号